ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti
The biotech’s challenger CAR-T is matching Carvytki in efficacy and showing an edge in safety in abstract data released ahead of the December meeting.
The biotech’s challenger CAR-T is matching Carvytki in efficacy and showing an edge in safety in abstract data released ahead of the December meeting.